Enhanc3D Genomics has appointed Daniel Turner as chief scientific officer to help drive the company’s development plans for its GenLink3D genomics platform and formation of commercial and academic partnerships. Dr Turner brings over 20 years of senior leadership in genetics, molecular biology, and sequencing research. He joined Enhanc3D Genomics from Oxford Nanopore Technologies Plc. He also was head of sequencing technology development at the Wellcome Trust Sanger Institute, UK. The appointment follows that of Hazel Jones as chief operating officer in November 2023.
Enhanc3D Genomics announced the appointment on 31 January.
Copyright 2024 Evernow Publishing Ltd